REVELATION BIOSCIENCES INC

REVB is the ticker symbol for Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company. The stock represents ownership in a business focused on developing immunology-based therapies. Because REVB is a small-cap, early-stage biotech, its prospects are tied more to clinical trial outcomes and regulatory progress than to commercial product sales. The shares trade on the Nasdaq Capital Market under the symbol REVB.

REVB operates in the biotechnology industry, specifically in the development of immunology-based therapeutics. The company concentrates on preclinical and clinical programs targeting respiratory and immune-related conditions. This places REVB among small-cap biopharma companies where research milestones, clinical data, and regulatory decisions are central drivers of the business.

The most current REVB price is shown on this page, along with intraday movement and other market data. Because biotech shares like REVB can move sharply on news, the displayed quote may change quickly. For the latest figures, refer to the live REVB data on this page rather than relying on older third-party sources.

As a small-cap clinical-stage biotech, REVB has historically experienced significant price volatility. Shares often react to clinical trial announcements, financing activity, and shifts in investor sentiment toward speculative biopharma names. Trading volume can also spike around company news. For the most current measure of REVB's price swings and volume, check the latest market data on this page.

REVB trades on the Nasdaq Capital Market, but its daily volume can vary notably around company-specific news and broader biotech market conditions. Liquidity may be thinner than that of large-cap stocks, which can lead to wider bid-ask spreads. The latest REVB trading volume and average volume are available in the market data displayed on this page.

REVB faces risks common to clinical-stage biopharmaceutical companies, including the possibility that drug candidates fail in trials, delays in regulatory review, and the need to raise additional capital to fund operations. Because the company may not have significant product revenue, its financial position depends on financing. REVB's stock may also be sensitive to changes in biotech sentiment and interest rates.